Oryzon Bolsters Iadademstat Patent Portfolio in Mexico
Event summary
- Oryzon Genomics secured a patent grant in Mexico covering combinations of its drug candidate, iadademstat, with PD-1/PD-L1 inhibitors.
- The patent, filed in 2021, protects the use of iadademstat in treating cancer, specifically targeting small cell lung cancer (SCLC).
- The patent is expected to provide protection until at least 2040, barring patent term extensions.
- Oryzon now holds patents for these combinations in Australia, Europe, Japan, Mexico, and Russia.
The big picture
This patent grant strengthens Oryzon’s IP position for iadademstat, a key component of its oncology pipeline. The combination with PD-1/PD-L1 inhibitors represents a strategic shift towards immunotherapy, a rapidly growing segment of the cancer treatment market. Securing patent protection in multiple regions is essential for Oryzon to attract investment and potentially out-license the technology to larger pharmaceutical companies.
What we're watching
- Clinical Progress
- The success of ongoing Phase I/II trials in SCLC, particularly the NCI-sponsored study, will be crucial in validating the combination therapy and justifying the patent’s value.
- Geographic Expansion
- The pace at which Oryzon pursues patent applications and grants in other key jurisdictions will influence the drug’s commercial potential and competitive landscape.
- Regulatory Risk
- How the EMA and FDA view the combination therapy, and whether they will grant accelerated approval pathways, will significantly impact Oryzon’s ability to monetize the patent.
Related topics